Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 5/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60395 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL5702178 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL60394 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL37390 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL3859589 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL124866 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL1592581 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL61487 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL5969692 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 | |
| SCHEMBL782450 | 1.00 | EPHX2 (0.55) | EPHX2FAAHCA2APPCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388596-A1 | PROCESS FOR THE EXTRACTION AND PURIFICATION OF TETRODOTOXIN | WEX PHARMACEUTICALS INC (CA) | 2025-12-25 | — | — | US | claimed |
| US-20250281426-A1 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2025-09-11 | — | — | US | claimed |
| EP-4448545-B1 | MANUFACTURING PROCESS FOR THE PRODUCTION OF LINACLOTIDE | CHEMI SPA (IT) | 2025-08-20 | — | — | EP | claimed |
| CN-119804678-A | Method for simultaneously detecting contents of two medicinal components in sample | 润尔眼科药物（广州）有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119738488-A | Method for measuring optical isomer of eplerenone by high performance liquid chromatography | 江苏嘉逸医药有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-119595798-A | High performance liquid chromatography for efficiently separating and detecting isomer impurities in fluvoxamine maleate | 河北医科大学 | 2025-03-11 | — | — | CN | claimed |
| CN-119395168-A | Method for detecting cystine and derivatives thereof | 远大医学营养科学(武汉)有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4501314-A1 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2025-02-05 | — | — | EP | claimed |
| WO-2023207730-A9 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | 宜昌人福药业有限责任公司 | 2024-11-07 | — | — | WO | claimed |
| CN-118624733-A | Method for detecting related substance RFC1 in revamping | 四川普锐特药业有限公司 | 2024-09-10 | — | — | CN | claimed |
| EP-1487838-A2 | METHOD AND SYSTEM FOR SEPARATION AND PURIFICATION OF AT LEAST ONE NARCOTIC ALKALOID USING REVERSE PHASE PREPARATIVE CHROMATOGRAPHY | Mallinckrodt Inc. (US) | 2004-12-22 | — | — | EP | claimed |
| WO-2003074526-A2 | METHOD AND SYSTEM FOR SEPARATION AND PURIFICATION OF AT LEAST ONE NARCOTIC ALKALOID USING REVERSE PHASE PREPARATIVE CHROMATOGRAPHY | MALLINCKRODT INC. (US) | 2003-09-12 | — | — | WO | claimed |
| US-6562968-B2 | Preparing sample by dissolving tetrodotoxin in a weak organic acid; applying tetrodotoxin solution to a chromatography column comprising an octyldecylsilane stationary phase and chromatographically separating sample using mobile phase | NANNING MAPLE LEAF PHARMACEUTICAL CO., LTD. (CN) | 2003-05-13 | — | — | US | claimed |
| US-20020099226-A1 | Method of purifying tetrodotoxin | WEX MEDICAL LIMITED (HK) | 2002-07-25 | — | — | US | claimed |
| US-20020086997-A1 | Method of isolating anhydro-tetrodotoxin | NANNING MAPLE LEAF PHARMACEUTICAL CO., LTD. (CN) | 2002-07-04 | — | — | US | claimed |
| WO-2002042308-A1 | A METHOD OF PURIFYING TETRODOTOXIN | NANNING MAPLE LEAF PHARMACEUTICAL CO., LTD. (CN) | 2002-05-30 | — | — | WO | claimed |
| US-5500668-A | INK JET PRINTING | XEROX CORPORATION (US) | 1996-03-19 | — | — | US | claimed |
| US-5034214-A | Alkali metal alkyl sulfonates or alkaline earth metal alkyl sulfonates | KRAFT GENERAL FOODS, INC. (US) | 1991-07-23 | — | — | US | claimed |
| US-4992279-A | Adding alkali metal or alkaline earth metal heptyl or octyl sulfonate(s) | KRAFT GENERAL FOODS, INC. (US) | 1991-02-12 | — | — | US | claimed |
| EP-0207515-A1 | An ingestible product containing a sweetness inhibitor and process for inhibiting sweetness in an ingestible product | GENERAL FOODS CORPORATION (US) | 1987-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281426-A1 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | GRIK5, GRIK1, GRIK3 | EPHX2 3209/4885FAAH 1438/4885CA2 3754/4885 |
| US-20020099226-A1 | Method of purifying tetrodotoxin | TMSB4X, INA, LTA | EPHX2 855/4885FAAH 1751/4885CA2 261/4885 |
| US-20020086997-A1 | Method of isolating anhydro-tetrodotoxin | TREH, DOHH, INA | EPHX2 550/4885FAAH 16/4885CA2 1011/4885 |
| US-20250388596-A1 | PROCESS FOR THE EXTRACTION AND PURIFICATION OF TETRODOTOXIN | TRPA1, CACNA1D, SCN2A | EPHX2 1692/4885FAAH 748/4885CA2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.